Mineralys Therapeutics (NASDAQ:MLYS) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Mineralys Therapeutics (NASDAQ:MLYS) posted its quarterly earnings data on Wednesday. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.02, Zacks reports.

Mineralys Therapeutics Stock Down 2.8 %

NASDAQ MLYS traded down $0.29 during trading hours on Thursday, hitting $10.34. The company’s stock had a trading volume of 21,395 shares, compared to its average volume of 260,531. The stock has a fifty day moving average of $11.21 and a 200 day moving average of $12.03. The firm has a market capitalization of $514.42 million, a P/E ratio of -3.15 and a beta of 1.44. Mineralys Therapeutics has a twelve month low of $8.58 and a twelve month high of $16.91.

Insider Activity

In other news, CFO Adam Scott Levy sold 10,757 shares of the company’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $9.10, for a total value of $97,888.70. Following the completion of the sale, the chief financial officer now directly owns 226,097 shares of the company’s stock, valued at $2,057,482.70. This represents a 4.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Jon Congleton sold 18,333 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $9.06, for a total transaction of $166,096.98. Following the completion of the sale, the chief executive officer now owns 877,608 shares in the company, valued at $7,951,128.48. This represents a 2.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 33.24% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Mineralys Therapeutics in a research note on Thursday.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.